Clinical Trials Logo
  1. Home
  2. Portal Vein Thrombosis
  3. NCT03193502
  4. Details
NCT03193502 Clinical Trial

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Portal Vein Thrombosis Clinical Trial

Official title:
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03193502
Other study ID # Amr Hanafy
Secondary ID
Status Recruiting
Phase Phase 3
First received June 17, 2017
Last updated October 12, 2017
Start date May 1, 2014
Est. completion date December 2020

Study information
Verified date October 2017
Source Tanta University
Contact Sherief Abd-Elsalam, consultant
Phone 00201095159522
Email Sheriefabdelsalam@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

-Rivaroxaban is factor Xa inhibitor

Description:

PVT is a common complication of liver cirrhosis

Recruitment information / eligibility
Status Recruiting
Enrollment 40
Est. completion date December 2020
Est. primary completion date July 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Acute PVT

Exclusion Criteria:

- Malignant PVT

- Bleeding disorders

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• rivaroxaban
rivaroxaban

Locations
Country Name City State
Egypt Tropical medicine dept.-Tanta university hospital Cairo

Sponsors (1)
Lead Sponsor Collaborator
Sherief Abd-Elsalam

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of patients with recanalized portal vein recanalization of portal vein 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT02250391 - Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis Phase 3
Recruiting NCT05625893 - Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion Phase 2
Completed NCT05012501 - Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
Terminated NCT00769873 - Anticoagulation Post Laparoscopic Splenectomy Phase 2
Recruiting NCT05123326 - Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Completed NCT01095185 - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Phase 3
Completed NCT02585713 - Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Phase 3
Not yet recruiting NCT06117488 - Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children
Completed NCT01326949 - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis N/A
Not yet recruiting NCT05339581 - IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation N/A
Recruiting NCT03902678 - Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma N/A
Not yet recruiting NCT06319131 - Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT N/A
Completed NCT03201367 - Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV N/A
Completed NCT03477149 - EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications N/A
Recruiting NCT02398357 - The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Phase 4
Completed NCT01556282 - TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis N/A
Withdrawn NCT01631877 - Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver N/A
Recruiting NCT04433481 - Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis N/A
Not yet recruiting NCT05872841 - H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis Phase 2